Baltimore, Maryland - AsclepiX Therapeutics, a pioneering biotechnology company focused on revolutionizing ocular disease treatment, announced today the successful completion of its Series A funding round, raising an impressive $10 million. The round was led by renowned investment firm Perceptive Advisors, solidifying the company's position as a frontrunner in the development of novel and durable therapies for ocular diseases.

Founded by esteemed visionary Robert Dempsey, AsclepiX Therapeutics has emerged as a leading player in the biotechnology industry. The company's cutting-edge research and development efforts are centered around addressing unmet medical needs and advancing innovative treatment solutions for ocular diseases that affect millions worldwide.

"We are immensely grateful to Perceptive Advisors for their unwavering confidence in our vision and technology," said Robert Dempsey, the founder of AsclepiX Therapeutics. "This significant funding milestone will enable us to accelerate the development of our proprietary treatments, which hold the potential to significantly improve the lives of patients suffering from debilitating ocular diseases."